Citizens Financial Group Inc. RI Acquires 558 Shares of IDEXX Laboratories, Inc. $IDXX

Citizens Financial Group Inc. RI grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53.1% during the second quarter, HoldingsChannel.com reports. The firm owned 1,608 shares of the company’s stock after acquiring an additional 558 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in IDEXX Laboratories were worth $863,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Jensen Investment Management Inc. increased its stake in IDEXX Laboratories by 27.1% in the 2nd quarter. Jensen Investment Management Inc. now owns 10,410 shares of the company’s stock worth $5,583,000 after buying an additional 2,220 shares during the period. Cetera Investment Advisers increased its position in shares of IDEXX Laboratories by 6.3% during the second quarter. Cetera Investment Advisers now owns 20,643 shares of the company’s stock worth $11,072,000 after acquiring an additional 1,223 shares during the period. Creative Planning increased its position in shares of IDEXX Laboratories by 11.7% during the second quarter. Creative Planning now owns 29,068 shares of the company’s stock worth $15,590,000 after acquiring an additional 3,052 shares during the period. WealthShield Partners LLC raised its stake in shares of IDEXX Laboratories by 114.9% during the second quarter. WealthShield Partners LLC now owns 2,746 shares of the company’s stock valued at $1,473,000 after acquiring an additional 1,468 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of IDEXX Laboratories by 5.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,724 shares of the company’s stock valued at $10,579,000 after purchasing an additional 998 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $670.21 on Wednesday. The firm has a 50 day moving average of $652.36 and a 200 day moving average of $592.66. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $53.52 billion, a price-to-earnings ratio of 55.80, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the business posted $2.80 EPS. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of several research reports. Jefferies Financial Group restated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, November 13th. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Finally, BTIG Research increased their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $730.50.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director owned 262 shares of the company’s stock, valued at approximately $169,600.46. This trade represents a 89.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.